Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate

CompletedOBSERVATIONAL
Enrollment

12

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

May 10, 2022

Study Completion Date

May 10, 2022

Conditions
Covid19
Interventions
DRUG

Fenofibrate

145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)

DRUG

Placebo

Matching placebo (once/day) for 10 days

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT05080192 - Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate | Biotech Hunter | Biotech Hunter